We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

85 hedge funds and large institutions have $202M invested in Corvus Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 8

150% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

53% more call options, than puts

Call options by funds: $15.5M | Put options by funds: $10.1M

37% more funds holding

Funds holding: 62 → 85 (+23)

27% more capital invested

Capital invested by funds: $159M → $202M (+$43.3M)

10.72% more ownership

Funds ownership: 48% → 58.72% (+11%)

Holders
85
Holders Change
+23
Holders Change %
+37.1%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
32
Increased
30
Reduced
12
Closed
8
Calls
$15.5M
Puts
$10.1M
Net Calls
+$5.36M
Net Calls Change
-$178K

Top Buyers

1
RI
RTW Investments
New York
+$20M
2
SC
Samlyn Capital
New York
+$16M
3
DM
Deerfield Management
New York
+$7.47M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.94M
5
VC
Vivo Capital
California
+$5.5M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$18.9M
2
Marshall Wace
Marshall Wace
United Kingdom
-$1.71M
3
SSA
Schonfeld Strategic Advisors
New York
-$1.51M
4
Millennium Management
Millennium Management
New York
-$1.17M
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$724K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$131K -$187K -25,101 -51%
AGM
52
Alpine Global Management
New York
$125K +$174K +23,282 New
Dimensional Fund Advisors
53
Dimensional Fund Advisors
Texas
$122K +$81.1K +10,869 +91%
TBWA
54
Three Bridge Wealth Advisors
California
$120K +$167K +22,371 New
QOP
55
Quinn Opportunity Partners
Virginia
$119K – – –
CB
56
Commerce Bank
Missouri
$107K – – –
GCM
57
Graham Capital Management
Connecticut
$97.9K +$137K +18,305 New
OC
58
Oppenheimer & Co
New York
$96.5K +$8.19K +1,097 +6%
Two Sigma Advisers
59
Two Sigma Advisers
New York
$95.8K -$324K -43,400 -71%
JG
60
Jain Global
New York
$88.8K +$124K +16,600 New
HF
61
HRT Financial
New York
$87K +$122K +16,388 New
VF
62
Virtu Financial
New York
$86K +$2.57K +344 +2%
NL
63
NWAM LLC
Washington
$82.9K +$40.7K +5,450 +54%
TRCT
64
Tower Research Capital (TRC)
New York
$73.9K +$103K +13,822 New
CUAMC
65
China Universal Asset Management Company
China
$72.9K +$102K +13,625 New
Man Group
66
Man Group
United Kingdom
$72.7K +$101K +13,594 New
ECM
67
ExodusPoint Capital Management
New York
$72K +$101K +13,516 New
WTC
68
WhitTier Trust Company
Nevada
$59.9K – – –
PAS
69
PKS Advisory Services
New York
$56.2K +$78.4K +10,500 New
VEA
70
Virtus ETF Advisers
New York
$47.1K +$65.7K +8,799 New
RIL
71
Rothschild Investment LLC
Illinois
$37.5K – – –
Royal Bank of Canada
72
Royal Bank of Canada
Ontario, Canada
$27K +$37.1K +4,964 New
NCM
73
Northwest Capital Management
Oregon
$18.2K – – –
Mirae Asset Global Investments
74
Mirae Asset Global Investments
South Korea
$11.2K +$16K +2,141 New
WPWM
75
Western Pacific Wealth Management
Illinois
$10.7K – – –
1 2
3
4

CRVS Hedge Fund Activity: Q4 2024 in Review

85 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2024, worth a combined $202M — up 27% from $159M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CRVS positions and 8 closed out — a net gain of 24 holders — while 30 added to existing stakes and 12 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $20M. The largest seller was Point72 Asset Management, cutting an estimated $18.9M.

  • 85 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2024, up from 62 in Q3 2024.
  • Funds reported $202M of Corvus Pharmaceuticals stock for Q4 2024, up 27% quarter-over-quarter.
  • 32 funds opened new Corvus Pharmaceuticals positions in Q4 2024 and 8 closed out, a net change of +24 holders.
  • The largest Corvus Pharmaceuticals buyer in Q4 2024 was RTW Investments, an estimated $20M added.
  • The largest Corvus Pharmaceuticals seller in Q4 2024 was Point72 Asset Management, an estimated $18.9M sold.

Based on aggregated 13F filings for Q4 2024.